ARHGEF1

Across TCGA pan-cancer cohorts, ARHGEF1 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ARHGEF1 data layer compared with 24 for mass-spec protein and 7 for mass-spec protein.

The strongest signal is observed in small cell lung cancer (SCLC), where higher ARHGEF1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ARHGEF1 expression acts as an unfavorable survival marker, although some lineages such as BLCA show a favorable association.

SCLC, BLCA, and SKCM are the cancer types where ARHGEF1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SCLC	OS	Median	II,III,IV	0.192	0.699	.002	18	view →
BLCA	DFS	Median	III,IV	1.000	0.265	.014	10	view →
SKCM	OS	Median	II,III,IV	0.245	0.731	.014	6	view →
LUAD	OS	Median	All	0.188	0.670	.049	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

ARHGEF1–SCLC (OS)

Open the SCLC breakdown →